Status:
COMPLETED
Co-administration of IVM and ALB in School-based Deworming in Uganda
Lead Sponsor:
Jennifer Keiser
Collaborating Sponsors:
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda
Makerere University
Conditions:
Helminthiasis
Intestinal Worms
Eligibility:
All Genders
5-14 years
Brief Summary
The goal of this small-scale implementation research pilot study is to assess the feasibility and acceptability of the co-administration of ivermectin (IVM) and albendazole (ALB) compared to albendazo...
Eligibility Criteria
Inclusion
- School-aged children (5-14 years) of the selected schools
- Written informed consent from the participant's parents/caretakers and assent (for children aged 8 years and older) from the participant him/herself or written informed consent from the school teacher (for children attending schools receiving routine albendazole deworming)
- No signs of major acute or chronic illness
- No known allergy to study medication (i.e. benzimidazoles or ivermectin)
Exclusion
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 19 2024
Estimated Enrollment :
8767 Patients enrolled
Trial Details
Trial ID
NCT06497075
Start Date
July 1 2024
End Date
October 19 2024
Last Update
December 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Makerere University, College of Humanities and Social Sciences
Kampala, Uganda
2
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
Kampala, Uganda